UY28706A1 - Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes - Google Patents
Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantesInfo
- Publication number
- UY28706A1 UY28706A1 UY28706A UY28706A UY28706A1 UY 28706 A1 UY28706 A1 UY 28706A1 UY 28706 A UY28706 A UY 28706A UY 28706 A UY28706 A UY 28706A UY 28706 A1 UY28706 A1 UY 28706A1
- Authority
- UY
- Uruguay
- Prior art keywords
- derivatives
- response
- proteoliposomas
- cytotox
- inducting
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000004044 response Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 108010030416 proteoliposomes Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010037075 Protozoal infections Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000007402 cytotoxic response Effects 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940021993 prophylactic vaccine Drugs 0.000 abstract 1
- 239000003725 proteoliposome Substances 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se presentan composiciones vacunales para el tratamiento efectivo o prevención de infecciones fúngicas, virales, protozoarias o bacterianas (preferiblemente intracelulares) y cáncer. Se obtienen adyuvantes para uso en vacunas profilácticas o terapéuticas utilizando Proteoliposomas bacterianos y sus derivados, que induzcan una respuestoa de linfocitos T citotóxica contra dicho antígeno. Así, se obtienen formulaciones múltiples del Proteoliposoma o sus derivados con antígenos heterólogos, que inducen respuestas citotóxicas. Este nuevo uso de los Proteoliposomas y sus derivados y las formulaciones antigénicas resultantes son aplicables a la obtención de nuevas vacunas en la industria farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030312A CU23420A1 (es) | 2003-12-30 | 2003-12-30 | Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28706A1 true UY28706A1 (es) | 2005-08-31 |
Family
ID=34716104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28706A UY28706A1 (es) | 2003-12-30 | 2004-12-30 | Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1716866A1 (es) |
| KR (1) | KR20070036020A (es) |
| AR (1) | AR051059A1 (es) |
| AU (1) | AU2004308553A1 (es) |
| BR (1) | BRPI0418332A (es) |
| CA (1) | CA2552271A1 (es) |
| CU (1) | CU23420A1 (es) |
| ES (1) | ES2301418B1 (es) |
| UY (1) | UY28706A1 (es) |
| WO (1) | WO2005063287A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20080215A7 (es) | 2008-11-19 | 2012-06-21 | Inst Finlay | Vacunas unitemporales |
| CU20100083A7 (es) | 2010-05-05 | 2012-06-21 | Inst Finlay | Tolerogenos adyuvados como vacuna de malaria |
| CU20110202A7 (es) | 2011-11-02 | 2013-12-27 | Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas | Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes |
| EP2689775A1 (en) | 2012-07-25 | 2014-01-29 | Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros | Cochleate with only one mamp |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2023448C1 (ru) * | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
| GB2282379A (en) * | 1993-09-30 | 1995-04-05 | Merck & Co Inc | Conjugates of epitopes of HIV with a protein complex from Neisseria |
| CA2438425C (en) * | 2001-03-09 | 2012-05-01 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
| CU22983A1 (es) * | 2002-05-08 | 2004-09-09 | Inst Finlay | Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas |
-
2003
- 2003-12-30 CU CU20030312A patent/CU23420A1/es unknown
-
2004
- 2004-12-28 ES ES200650046A patent/ES2301418B1/es not_active Expired - Fee Related
- 2004-12-28 BR BRPI0418332-0A patent/BRPI0418332A/pt not_active Application Discontinuation
- 2004-12-28 AU AU2004308553A patent/AU2004308553A1/en not_active Abandoned
- 2004-12-28 KR KR1020067014392A patent/KR20070036020A/ko not_active Application Discontinuation
- 2004-12-28 EP EP04802609A patent/EP1716866A1/en not_active Ceased
- 2004-12-28 CA CA002552271A patent/CA2552271A1/en not_active Abandoned
- 2004-12-28 WO PCT/CU2004/000017 patent/WO2005063287A1/es active IP Right Grant
- 2004-12-29 AR ARP040104938A patent/AR051059A1/es unknown
- 2004-12-30 UY UY28706A patent/UY28706A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004308553A1 (en) | 2005-07-14 |
| BRPI0418332A (pt) | 2008-02-06 |
| ES2301418A1 (es) | 2008-06-16 |
| EP1716866A1 (en) | 2006-11-02 |
| CU23420A1 (es) | 2009-09-08 |
| ES2301418B1 (es) | 2009-05-01 |
| WO2005063287A1 (es) | 2005-07-14 |
| CA2552271A1 (en) | 2005-07-14 |
| KR20070036020A (ko) | 2007-04-02 |
| AR051059A1 (es) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR11122A (es) | Vacuna de influenza de emulsion de aceite en agua | |
| CY1121789T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
| CU23404A1 (es) | Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes | |
| CY1115308T1 (el) | Συνθεσεις εμβολιου οι οποιες περιεχουν ανοσοενισχυτικο εκδοχο σαπωνινης | |
| CY1121535T1 (el) | Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων | |
| BR112018004242A2 (pt) | composições de vacina que possuem estabilidade e imunogenicidade aumentadas | |
| CY1113546T1 (el) | Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων | |
| CR10559A (es) | Vacuna de influenza | |
| CY1116904T1 (el) | Εμβολιο | |
| CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
| CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
| MX2020008454A (es) | Composicion inmunogenica que comprende antigenos estafilococicos. | |
| AR080111A1 (es) | Metodos y composiciones de inmunizacion | |
| AR059647A1 (es) | Antigenos vacunales quimericos contra el virus de la influenza aviar | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| AR115069A1 (es) | Virus vacuna quimérico sintético | |
| BRPI0606165A2 (pt) | método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada | |
| UY28706A1 (es) | Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes | |
| CU20080215A7 (es) | Vacunas unitemporales | |
| CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
| WO2021207281A3 (en) | Vaccines, adjuvants, and methods of generating an immune response | |
| CL2020002876A1 (es) | Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420) | |
| AR093530A1 (es) | Adyuvante de vacunacion, preparacion, y vacunas que lo contienen | |
| AR038311A1 (es) | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes | |
| CY1125762T1 (el) | Νεα απο του στοματος σκευασματα βελινοστατης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20160617 |